User profiles for J. Pepke-Zaba

Joanna Pepke-Zaba

Papworth Hospital
Verified email at virginmedia.com
Cited by 90225

2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: Developed by the task force for the diagnosis and treatment of pulmonary …

…, B Nagavci, KM Olsson, J Pepke-Zaba… - European heart …, 2022 - academic.oup.com
Pulmonary hypertension (PH) is a pathophysiological disorder that may involve multiple
clinical conditions and may be associated with a variety of cardiovascular and respiratory …

Pulmonary arterial hypertension: epidemiology and registries

…, X Jiang, DP Miller, AJ Peacock, J Pepke-Zaba… - Journal of the American …, 2013 - jacc.org
Registries of patients with pulmonary arterial hypertension (PAH) have been instrumental in
characterizing the presentation and natural history of the disease and provide a basis for …

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

…, R Naeije, H Olschewski, J Pepke-Zaba… - Journal of the American …, 2009 - jacc.org
The 4th World Symposium on Pulmonary Hypertension was the first international meeting to
focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH …

Inhaled nitric oxide as a cause of selective pulmonary vasodilatation in pulmonary hypertension

J Pepke-Zaba, TW Higenbottam, AT Dinh-Xuan… - The Lancet, 1991 - Elsevier
The acute effects of inhaled nitric oxide (NO) (40 ppm in air) on pulmonary (PVR) and
systemic (SVR) vascular resistance were compared with those of an intravenous infusion of …

Chronic thromboembolic pulmonary hypertension (CTEPH) results from an international prospective registry

J Pepke-Zaba, M Delcroix, I Lang, E Mayer, P Jansa… - Circulation, 2011 - Am Heart Assoc
… Dr Pepke-Zaba has received honoraria for lecturing from Bayer , Actelion , Pfizer , and GSK
, and is on advisory boards for Actelion, Pfizer, Bayer, GSK, United Therapeutics, and Eli Lilly…

Connective tissue disease–associated pulmonary arterial hypertension in the modern treatment era

…, D Hodgkins, RJ Hughes, J Pepke-Zaba… - American journal of …, 2009 - atsjournals.org
Rationale: Pulmonary arterial hypertension in association with connective tissue disease (CTD-PAH)
has historically had a poor prognosis, with a 1-year survival rate among patients …

[HTML][HTML] Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry

…, W Klepetko, M Delcroix, I Lang, J Pepke-Zaba… - The Journal of thoracic …, 2011 - Elsevier
OBJECTIVE: Pulmonary endarterectomy is a curative surgical treatment option for the majority
of patients with chronic thromboembolic pulmonary hypertension. The current surgical …

Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension

…, P Nicklin, C Walker, DC Budd, J Pepke-Zaba… - Circulation, 2010 - Am Heart Assoc
Background— Inflammation is a feature of pulmonary arterial hypertension (PAH), and
increased circulating levels of cytokines are reported in patients with PAH. However, to date, no …

Changing demographics, epidemiology, and survival of incident pulmonary arterial hypertension: results from the pulmonary hypertension registry of the United …

…, JSR Gibbs, LS Howard, J Pepke-Zaba… - American journal of …, 2012 - atsjournals.org
Rationale: Incident pulmonary arterial hypertension was underrepresented in most pulmonary
hypertension registries and may have a different disease profile to prevalent disease. …

Bosentan for treatment of inoperable chronic thromboembolic pulmonary hypertension: BENEFiT (Bosentan Effects in iNopErable Forms of chronIc Thromboembolic …

…, MM Hoeper, IM Lang, E Mayer, J Pepke-Zaba… - Journal of the American …, 2008 - jacc.org
Objectives : Our goal was to investigate the effect of treatment with the oral dual endothelin
receptor antagonist bosentan on the hemodynamics and exercise capacity of patients with …